Trials / Unknown
UnknownNCT03216070
Low-dose Dasatinib as First-line Treatment for Chronic Myeloid Leukemia
- Status
- Unknown
- Phase
- Phase 4
- Study type
- Interventional
- Enrollment
- 12 (estimated)
- Sponsor
- Hospital Universitario Dr. Jose E. Gonzalez · Academic / Other
- Sex
- Female
- Age
- 16 Years
- Healthy volunteers
- Not accepted
Summary
Our goal is to demonstrate that 50mg of dasatinib is as effective as the full dose to induce molecular response as first line therapy in CML.
Detailed description
We will give 50mg of dasatinib daily since the diagnosis for up to 6 months, for the first 2-4 weeks we will evaluate hematic biometry to registry hematic response, at months 3 and 6 a BCR/ABL PCR will be taken to evaluate molecular response.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Dasatinib 50 MG | 50mg of dasatinib orally daily |
Timeline
- Start date
- 2016-04-01
- Primary completion
- 2018-10-01
- Completion
- 2018-10-01
- First posted
- 2017-07-13
- Last updated
- 2017-07-13
Locations
1 site across 1 country: Mexico
Source: ClinicalTrials.gov record NCT03216070. Inclusion in this directory is not an endorsement.